Results 141 to 150 of about 5,754,962 (309)
ABSTRACT Objective Onasemnogene abeparvovec (OA) is an AAV9‐based gene therapy for spinal muscular atrophy type I (SMA I). Real‐world outcomes show increased response variability compared to clinical trials, and follow‐up data beyond 12–18 months are limited.
Marika Pane +43 more
wiley +1 more source
The Three Dimensions of Engagement
Dr Ella Kahu - The Three Dimensions of Engagement (2019 First Year Experience Learning and Teaching Forum, University of the Sunshine Coast, Australia) 1.30 minutes.
Ella Kahu
doaj +1 more source
The First Year Experience of Newborn Screening for Pompe Disease in California. [PDF]
Tang H +6 more
europepmc +1 more source
Creating a First Year experience
Retaining students and supporting transition to Higher Education are key issues facing many Higher Education institutions. The recent study on progression in Irish Higher Education conducted by the HEA found that an average of 15% of new undergraduate entrants failed to progress into the second year of their programme. (HEA, 2010).
Farrell, Orna, Brunton, James
openaire +1 more source
Exploring the Developmental Outcomes of First-Year Experience Seminars (in-progress) [PDF]
A substantial amount of research shows that the first year of college is a “make or break” time for most students, with an estimated 60% of incoming students withdrawing before the beginning of their sophomore year (Pascarella & Terenzini, 2005 ...
Guarneri, Joseph A.
core
A Depolarizing Leak in Sodium Bicarbonate Cotransporter NBCe1 Causes Brain Edema
ABSTRACT Objectives SLC4A4 encodes electrogenic sodium bicarbonate cotransporter NBCe1, prominently expressed in kidney and brain. Recessive loss‐of‐function variants in SLC4A4 cause proximal renal tubular acidosis, no brain edema. In the brain, NBCe1 is expressed by astrocytes, where it regulates pH and mediates astrocyte volume changes.
Quinty Bisseling +16 more
wiley +1 more source
Multiple Sclerosis Relapse Activity After Ozanimod Discontinuation in DAYBREAK Trial Participants
Multiple Sclerosis Relapse Activity After Ozanimod Discontinuation in DAYBREAK Trial Participants. ABSTRACT Objective Return of disease activity is expected when patients discontinue disease‐modifying therapy (DMT) for multiple sclerosis (MS). Some MS DMTs are associated with higher‐than‐expected disease activity (rebound) after discontinuation.
Ralf Gold +12 more
wiley +1 more source
ABSTRACT Objective Stereoelectroencephalography‐guided radiofrequency thermocoagulation (SEEG‐RFTC) has emerged as a safe and effective minimally invasive treatment for children with drug‐resistant focal epilepsy. Although evidence from real‐world studies remains limited, numerous pediatric cases have demonstrated promising outcomes. This retrospective
Weitao Chen +7 more
wiley +1 more source
First-Year Experience in Perspective
Entire Online Version of the Journal of Student Affairs in Africa, Vol. 6 Issue 1 (2018).
openaire +1 more source

